Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astria Therapeutics Inc (ATXS)

Astria Therapeutics Inc (ATXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders voted to approve the acquisition of Astria...

ATXS : 12.58 (+0.64%)
Halper Sadeh LLC Encourages CSGS, JHG, CWAN, ATXS Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

ATXS : 12.58 (+0.64%)
CSGS : 79.59 (-0.16%)
JHG : 48.22 (-0.04%)
CWAN : 23.60 (-0.88%)
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

NEW YORK and NEW ORLEANS , Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating the...

ATXS : 12.58 (+0.64%)
BCRX : 6.84 (+4.43%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR

NEW YORK , Dec. 19, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

ATXS : 12.58 (+0.64%)
SEMR : 11.83 (-0.08%)
MBCN : 34.51 (-0.35%)
FMNB : 13.41 (-0.52%)
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 12.58 (+0.64%)
TCBX : 41.75 (-2.70%)
RNA : 72.92 (+0.04%)
FSUN : 38.77 (-2.17%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

ATXS : 12.58 (+0.64%)
TCBX : 41.75 (-2.70%)
RNA : 72.92 (+0.04%)
FSUN : 38.77 (-2.17%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

ATXS : 12.58 (+0.64%)
SPNS : 43.45 (+0.02%)
PCH : 41.73 (+0.05%)
RYN : 22.36 (-0.31%)
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 12.58 (+0.64%)
MRUS : 90.00 (-7.14%)
HSII : 59.01 (+0.07%)
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

-- BioCryst’s Acquisition of Astria Expected to Close in the First Quarter of 2026 -- -- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned...

ATXS : 12.58 (+0.64%)
BCRX : 6.84 (+4.43%)
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

-- Final ALPHA-STAR Phase 1b/2 Results from the Full-Enrollment Population (n=29) Remain Highly Consistent with Prior Results from the Target-Enrollment Population (n=16), Demonstrating Strong Efficacy,...

ATXS : 12.58 (+0.64%)

Barchart Exclusives

This Outperforming Dividend Stock Increased Its 2026 Payout by 20%: Should You Buy?
GM increased its 2026 dividend by 20%, and while its dividend yield is below Ford's, it looks like a better buy compared to the Blue Oval. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar